AN AUTOLOGOUS THERAPEUTIC VACCINE BASED ON AN UNPRECEDENTED APPROACH
Urodelia has developed an autologous therapeutic vaccine combining proteins from tumor cells with hydroxyapatite.
The therapeutic vaccine in development by Urodelia under the name apa.vac® is part of the first category. Anti-cancer treatments in the most advanced immunotherapy to date are represented by two families: immune inhibitor checkpoint (ICI) and CAR T cells2 . They act in a very specific way on a particular blocking point of the patients’ immune defense, with promising results.
The therapeutic vaccine developed by Urodelia differs from other therapies due to its global action against the phenomenon of cancer cell proliferation at a given time, thus stimulating the patient’s immunity in response to the constant evolution of the disease. Two approaches are being explored:
- Customized vaccines designed from tumor biopsies or well -identified tumor antigens, which make it ossible to redirect the immune system against the tumor.
- Attenuated vaccines based on oncolytic viruses targeting tumors (ex herpes virus, Measles, adenovirus)